NCT01897441
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Not Applicable
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with stage IV disease are also eligible if there is an intention to perform breast surgery after neoadjuvant therapy is completed
Exclusions: 
https://ClinicalTrials.gov/show/NCT01897441